EU-1-04-273,https://www.ema.europa.eu/documents/scientific-discussion/lysodren-epar-scientific-discussion_en.pdf
EU-1-04-274,https://www.ema.europa.eu/documents/scientific-discussion/velcade-epar-scientific-discussion_en.pdf
EU-1-04-275,https://www.ema.europa.eu/documents/scientific-discussion/litak-epar-scientific-discussion_en.pdf
EU-1-98-091,https://www.ema.europa.eu/documents/scientific-discussion/kinzalmono-epar-scientific-discussion_en.pdf
EU-1-04-278,https://www.ema.europa.eu/documents/scientific-discussion/levemir-epar-scientific-discussion_en.pdf
EU-1-04-276,https://www.ema.europa.eu/documents/scientific-discussion/abilify-epar-scientific-discussion_en.pdf
EU-1-04-277,https://www.ema.europa.eu/documents/scientific-discussion/tachosil-epar-scientific-discussion_en.pdf
EU-1-04-281,https://www.ema.europa.eu/documents/scientific-discussion/erbitux-epar-scientific-discussion_en.pdf
EU-1-04-282,https://www.ema.europa.eu/documents/scientific-discussion/telzir-epar-scientific-discussion_en.pdf
EU-1-04-279,https://www.ema.europa.eu/documents/scientific-discussion/lyrica-epar-scientific-discussion_en.pdf
EU-1-04-280,https://www.ema.europa.eu/documents/scientific-discussion/yentreve-epar-scientific-discussion_en.pdf
EU-1-04-284,https://www.ema.europa.eu/documents/scientific-discussion/pedea-epar-scientific-discussion_en.pdf
EU-1-04-285,https://www.ema.europa.eu/documents/scientific-discussion/apidra-epar-scientific-discussion_en.pdf
EU-1-04-286,https://www.ema.europa.eu/documents/scientific-discussion/wilzin-epar-scientific-discussion_en.pdf
EU-1-04-290,https://www.ema.europa.eu/documents/scientific-discussion/alimta-epar-scientific-discussion_en.pdf
EU-1-04-292,https://www.ema.europa.eu/documents/scientific-discussion/mimpara-epar-scientific-discussion_en.pdf
EU-1-04-294,https://www.ema.europa.eu/documents/scientific-discussion/emselex-epar-scientific-discussion_en.pdf
EU-1-04-295,https://www.ema.europa.eu/documents/scientific-discussion/xagrid-epar-scientific-discussion_en.pdf
EU-1-04-296,https://www.ema.europa.eu/documents/scientific-discussion/cymbalta-epar-scientific-discussion_en.pdf
EU-1-04-298,https://www.ema.europa.eu/documents/scientific-discussion/kivexa-epar-scientific-discussion_en.pdf
EU-1-04-299,https://www.ema.europa.eu/documents/scientific-discussion/fendrix-epar-scientific-discussion_en.pdf
EU-1-04-300,https://www.ema.europa.eu/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf
EU-1-04-302,https://www.ema.europa.eu/documents/scientific-discussion/prialt-epar-scientific-discussion_en.pdf
EU-1-04-303,https://www.ema.europa.eu/documents/scientific-discussion/orfadin-epar-scientific-discussion_en.pdf
EU-1-04-305,https://www.ema.europa.eu/documents/scientific-discussion/truvada-epar-scientific-discussion_en.pdf
EU-1-04-304,https://www.ema.europa.eu/documents/scientific-discussion/azilect-epar-scientific-discussion_en.pdf
EU-1-04-306,https://www.ema.europa.eu/documents/scientific-discussion/aloxi-epar-scientific-discussion_en.pdf
EU-1-04-307,https://www.ema.europa.eu/documents/scientific-discussion/zonegran-epar-scientific-discussion_en.pdf
EU-1-05-308,https://www.ema.europa.eu/documents/scientific-discussion/aclasta-epar-scientific-discussion_en.pdf
EU-1-05-310,https://www.ema.europa.eu/documents/scientific-discussion/fosavance-epar-scientific-discussion_en.pdf
EU-1-05-311,https://www.ema.europa.eu/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf
EU-1-05-312,https://www.ema.europa.eu/documents/scientific-discussion/xyrem-epar-scientific-discussion_en.pdf
EU-1-05-315,https://www.ema.europa.eu/documents/scientific-discussion/aptivus-epar-scientific-discussion_en.pdf
EU-1-05-316,https://www.ema.europa.eu/documents/scientific-discussion/procoralan-epar-scientific-discussion_en.pdf
EU-1-05-317,https://www.ema.europa.eu/documents/scientific-discussion/corlentor-epar-scientific-discussion_en.pdf
EU-1-05-320,https://www.ema.europa.eu/documents/scientific-discussion/noxafil-epar-scientific-discussion_en.pdf
EU-1-05-319,https://www.ema.europa.eu/documents/scientific-discussion/xolair-epar-scientific-discussion_en.pdf
EU-1-05-318,https://www.ema.europa.eu/documents/scientific-discussion/revatio-epar-scientific-discussion_en.pdf
EU-1-05-322,https://www.ema.europa.eu/documents/scientific-discussion/yttriga-epar-scientific-discussion_en.pdf
EU-1-05-323,https://www.ema.europa.eu/documents/scientific-discussion/proquad-epar-scientific-discussion_en.pdf
EU-1-05-324,https://www.ema.europa.eu/documents/scientific-discussion/naglazyme-epar-scientific-discussion_en.pdf
EU-1-05-328,https://www.ema.europa.eu/documents/scientific-discussion/cubicin-epar-scientific-discussion_en.pdf
EU-1-05-329,https://www.ema.europa.eu/documents/scientific-discussion/kiovig-epar-scientific-discussion_en.pdf
EU-1-05-330,https://www.ema.europa.eu/documents/scientific-discussion/rotarix-epar-scientific-discussion_en.pdf
EU-1-05-331,https://www.ema.europa.eu/documents/scientific-discussion/neupro-epar-scientific-discussion_en.pdf
EU-1-06-332,https://www.ema.europa.eu/documents/scientific-discussion/omnitrope-epar-scientific-discussion_en.pdf
EU-1-06-333,https://www.ema.europa.eu/documents/scientific-discussion/myozyme-epar-scientific-discussion_en.pdf
EU-1-06-336,https://www.ema.europa.eu/documents/scientific-discussion/tygacil-epar-scientific-discussion_en.pdf
EU-1-06-337,https://www.ema.europa.eu/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf
EU-1-06-334,https://www.ema.europa.eu/documents/scientific-discussion/evoltra-epar-scientific-discussion_en.pdf
EU-1-06-338,https://www.ema.europa.eu/documents/scientific-discussion/duotrav-epar-scientific-discussion_en.pdf
EU-1-06-340,https://www.ema.europa.eu/documents/scientific-discussion/ganfort-epar-scientific-discussion_en.pdf
EU-1-06-341,https://www.ema.europa.eu/documents/scientific-discussion/zostavax-epar-scientific-discussion_en.pdf
EU-1-06-342,https://www.ema.europa.eu/documents/scientific-discussion/nexavar-epar-scientific-discussion_en.pdf
EU-1-06-346,https://www.ema.europa.eu/documents/scientific-discussion/tysabri-epar-scientific-discussion_en.pdf
EU-1-06-347,https://www.ema.europa.eu/documents/scientific-discussion/sutent-epar-scientific-discussion_en.pdf
EU-1-06-343,https://www.ema.europa.eu/documents/scientific-discussion/baraclude-epar-scientific-discussion_en.pdf
EU-1-06-348,https://www.ema.europa.eu/documents/scientific-discussion/rotateq-epar-scientific-discussion_en.pdf
EU-1-06-350,https://www.ema.europa.eu/documents/scientific-discussion/savene-epar-scientific-discussion_en.pdf
EU-1-06-354,https://www.ema.europa.eu/documents/scientific-discussion/competact-epar-scientific-discussion_en.pdf
EU-1-06-356,https://www.ema.europa.eu/documents/scientific-discussion/exjade-epar-scientific-discussion_en.pdf
EU-1-06-357,https://www.ema.europa.eu/documents/scientific-discussion/gardasil-epar-scientific-discussion_en.pdf
EU-1-06-359,https://www.ema.europa.eu/documents/scientific-discussion/suboxone-epar-scientific-discussion_en.pdf
EU-1-06-360,https://www.ema.europa.eu/documents/scientific-discussion/champix-epar-scientific-discussion_en.pdf
EU-1-06-361,https://www.ema.europa.eu/documents/scientific-discussion/luminity-epar-scientific-discussion_en.pdf
EU-1-06-362,https://www.ema.europa.eu/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf
EU-1-06-363,https://www.ema.europa.eu/documents/scientific-discussion/sprycel-epar-scientific-discussion_en.pdf
EU-1-06-367,https://www.ema.europa.eu/documents/scientific-discussion/diacomit-epar-scientific-discussion_en.pdf
EU-1-06-364,https://www.ema.europa.eu/documents/scientific-discussion/adrovance-epar-scientific-discussion_en.pdf
EU-1-06-365,https://www.ema.europa.eu/documents/scientific-discussion/elaprase-epar-scientific-discussion_en.pdf
EU-1-06-366,https://www.ema.europa.eu/documents/scientific-discussion/tandemact-epar-scientific-discussion_en.pdf
EU-1-06-378,https://www.ema.europa.eu/documents/scientific-discussion/inovelon-epar-scientific-discussion_en.pdf
EU-1-06-376,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-winthrop-epar-scientific-discussion_en.pdf
EU-1-06-370,https://www.ema.europa.eu/documents/procedural-steps/exforge-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-06-372,https://www.ema.europa.eu/documents/scientific-discussion/copalia-epar-scientific-discussion_en.pdf
EU-1-06-371,https://www.ema.europa.eu/documents/scientific-discussion/dafiro-epar-scientific-discussion_en.pdf
EU-1-06-374,https://www.ema.europa.eu/documents/scientific-discussion/lucentis-epar-scientific-discussion_en.pdf
EU-1-06-377,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-hydrochlorothiazide-winthrop-epar-scientific-discussion_en.pdf
EU-1-06-380,https://www.ema.europa.eu/documents/scientific-discussion/prezista-epar-scientific-discussion_en.pdf
EU-1-06-379,https://www.ema.europa.eu/documents/scientific-discussion/cystadane-epar-scientific-discussion_en.pdf
EU-1-07-382,https://www.ema.europa.eu/documents/scientific-discussion/xelevia-epar-scientific-discussion_en.pdf
EU-1-07-383,https://www.ema.europa.eu/documents/scientific-discussion/januvia-epar-scientific-discussion_en.pdf
EU-1-07-387,https://www.ema.europa.eu/documents/scientific-discussion/advagraf-epar-scientific-discussion_en.pdf
EU-1-07-386,https://www.ema.europa.eu/documents/scientific-discussion/toviaz-epar-scientific-discussion_en.pdf
EU-1-07-389,https://www.ema.europa.eu/documents/scientific-discussion/orencia-epar-scientific-discussion_en.pdf
EU-1-07-391,https://www.ema.europa.eu/documents/scientific-discussion/revlimid-epar-scientific-discussion_en.pdf
EU-1-07-392,https://www.ema.europa.eu/documents/scientific-discussion/circadin-epar-scientific-discussion_en.pdf
EU-1-07-393,https://www.ema.europa.eu/documents/scientific-discussion/soliris-epar-scientific-discussion_en.pdf
EU-1-07-396,https://www.ema.europa.eu/documents/scientific-discussion/pergoveris-epar-scientific-discussion_en.pdf
EU-1-07-395,https://www.ema.europa.eu/documents/scientific-discussion/invega-epar-scientific-discussion_en.pdf
EU-1-07-397,https://www.ema.europa.eu/documents/scientific-discussion/siklos-epar-scientific-discussion_en.pdf
EU-1-07-400,https://www.ema.europa.eu/documents/procedural-steps/mircera-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-399,https://www.ema.europa.eu/documents/scientific-discussion/aerinaze-epar-scientific-discussion_en.pdf
EU-1-07-401,https://www.ema.europa.eu/documents/scientific-discussion/alli-epar-scientific-discussion_en.pdf
EU-1-07-402,https://www.ema.europa.eu/documents/scientific-discussion/increlex-epar-scientific-discussion_en.pdf
EU-1-07-403,https://www.ema.europa.eu/documents/scientific-discussion/atriance-epar-scientific-discussion_en.pdf
EU-1-07-404,https://www.ema.europa.eu/documents/procedural-steps/flebogammadif-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-412,https://www.ema.europa.eu/documents/scientific-discussion/abseamed-epar-scientific-discussion_en.pdf
EU-1-07-405,https://www.ema.europa.eu/documents/scientific-discussion/rasilez-epar-scientific-discussion_en.pdf
EU-1-07-410,https://www.ema.europa.eu/documents/scientific-discussion/binocrit-epar-scientific-discussion_en.pdf
EU-1-07-411,https://www.ema.europa.eu/documents/scientific-discussion/epoetin-alfa-hexal-epar-scientific-discussion_en.pdf
EU-1-07-413,https://www.ema.europa.eu/documents/scientific-discussion/gliolan-epar-scientific-discussion_en.pdf
EU-1-07-414,https://www.ema.europa.eu/documents/scientific-discussion/galvus-epar-scientific-discussion_en.pdf
EU-1-07-415,https://www.ema.europa.eu/documents/scientific-discussion/zalasta-epar-scientific-discussion_en.pdf
EU-1-07-416,https://www.ema.europa.eu/documents/scientific-discussion/ecalta-epar-scientific-discussion_en.pdf
EU-1-07-417,https://www.ema.europa.eu/documents/scientific-discussion/yondelis-epar-scientific-discussion_en.pdf
EU-1-07-418,https://www.ema.europa.eu/documents/scientific-discussion/celsentri-epar-scientific-discussion_en.pdf
EU-1-07-419,https://www.ema.europa.eu/documents/scientific-discussion/cervarix-epar-scientific-discussion_en.pdf
EU-1-07-424,https://www.ema.europa.eu/documents/scientific-discussion/torisel-epar-scientific-discussion_en.pdf
EU-1-07-420,https://www.ema.europa.eu/documents/procedural-steps/cyanokit-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-425,https://www.ema.europa.eu/documents/scientific-discussion/eucreas-epar-scientific-discussion_en.pdf
EU-1-07-422,https://www.ema.europa.eu/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf
EU-1-07-423,https://www.ema.europa.eu/documents/scientific-discussion/vectibix-epar-scientific-discussion_en.pdf
EU-1-07-427,https://www.ema.europa.eu/documents/scientific-discussion/olanzapine-teva-epar-scientific-discussion_en.pdf
EU-1-07-431,https://www.ema.europa.eu/documents/scientific-discussion/retacrit-epar-scientific-discussion_en.pdf
EU-1-07-432,https://www.ema.europa.eu/documents/scientific-discussion/silapo-epar-scientific-discussion_en.pdf
EU-1-07-433,https://www.ema.europa.eu/documents/scientific-discussion/nevanac-epar-scientific-discussion_en.pdf
EU-1-07-428,https://www.ema.europa.eu/documents/assessment-report/abraxane-epar-public-assessment-report_en.pdf
EU-1-07-434,https://www.ema.europa.eu/documents/scientific-discussion/avamys-epar-scientific-discussion_en.pdf
EU-1-07-436,https://www.ema.europa.eu/documents/scientific-discussion/isentress-epar-scientific-discussion_en.pdf
EU-1-07-438,https://www.ema.europa.eu/documents/assessment-report/myfenax-epar-public-assessment-report_en.pdf
EU-1-07-439,https://www.ema.europa.eu/documents/assessment-report/mycophenolate-mofetil-teva-epar-public-assessment-report_en.pdf
EU-1-07-440,https://www.ema.europa.eu/documents/assessment-report/tyverb-epar-public-assessment-report_en.pdf
EU-1-08-441,https://www.ema.europa.eu/documents/scientific-discussion/effentora-epar-scientific-discussion_en.pdf
EU-1-08-442,https://www.ema.europa.eu/documents/assessment-report/pradaxa-epar-public-assessment-report_en.pdf
EU-1-08-446,https://www.ema.europa.eu/documents/assessment-report/privigen-epar-public-assessment-report_en.pdf
EU-1-08-447,https://www.ema.europa.eu/documents/assessment-report/adenuric-epar-public-assessment-report_en.pdf
EU-1-95-003,https://www.ema.europa.eu/documents/scientific-discussion/betaferon-epar-scientific-discussion_en.pdf
EU-1-95-002,https://www.ema.europa.eu/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf
EU-1-96-005,https://www.ema.europa.eu/documents/scientific-discussion/cellcept-epar-scientific-discussion_en.pdf
EU-1-96-004,https://www.ema.europa.eu/documents/scientific-discussion/fareston-epar-scientific-discussion_en.pdf
EU-1-96-006,https://www.ema.europa.eu/documents/scientific-discussion/novoseven-epar-scientific-discussion_en.pdf
EU-1-96-007,https://www.ema.europa.eu/documents/scientific-discussion/humalog-epar-scientific-discussion_en.pdf
EU-1-96-008,https://www.ema.europa.eu/documents/scientific-discussion/puregon-epar-scientific-discussion_en.pdf
EU-1-96-012,https://www.ema.europa.eu/documents/scientific-discussion/bondronat-epar-scientific-discussion_en.pdf
EU-1-97-033,https://www.ema.europa.eu/documents/scientific-discussion/avonex-epar-scientific-discussion_en.pdf
EU-1-96-018,https://www.ema.europa.eu/documents/scientific-discussion/rapilysin-epar-scientific-discussion_en.pdf
EU-1-96-010,https://www.ema.europa.eu/documents/scientific-discussion/rilutek-epar-scientific-discussion_en.pdf
EU-1-96-020,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-adult-epar-scientific-discussion_en.pdf
EU-1-96-022,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-epar-scientific-discussion_en.pdf
EU-1-97-031,https://www.ema.europa.eu/documents/scientific-discussion/neorecormon-epar-scientific-discussion_en.pdf
EU-1-96-027,https://www.ema.europa.eu/documents/scientific-discussion/hycamtin-epar-scientific-discussion_en.pdf
EU-1-96-015,https://www.ema.europa.eu/documents/scientific-discussion/epivir-epar-scientific-discussion_en.pdf
EU-1-96-016,https://www.ema.europa.eu/documents/scientific-discussion/norvir-epar-scientific-discussion_en.pdf
EU-1-97-029,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-paediatric-epar-scientific-discussion_en.pdf
EU-1-97-044,https://www.ema.europa.eu/documents/scientific-discussion/tasmar-epar-scientific-discussion_en.pdf
EU-1-97-039,https://www.ema.europa.eu/documents/scientific-discussion/cystagon-epar-scientific-discussion_en.pdf
EU-1-97-045,https://www.ema.europa.eu/documents/scientific-discussion/helicobacter-test-infai-epar-scientific-discussion_en.pdf
EU-1-97-046,https://www.ema.europa.eu/documents/scientific-discussion/aprovel-epar-scientific-discussion_en.pdf
EU-1-97-047,https://www.ema.europa.eu/documents/scientific-discussion/benefix-epar-scientific-discussion_en.pdf
EU-1-97-049,https://www.ema.europa.eu/documents/scientific-discussion/karvea-epar-scientific-discussion_en.pdf
EU-1-97-051,https://www.ema.europa.eu/documents/scientific-discussion/mirapexin-epar-scientific-discussion_en.pdf
EU-1-97-050,https://www.ema.europa.eu/documents/scientific-discussion/sifrol-epar-scientific-discussion_en.pdf
EU-1-97-053,https://www.ema.europa.eu/documents/scientific-discussion/cerezyme-epar-scientific-discussion_en.pdf
EU-1-97-057,https://www.ema.europa.eu/documents/scientific-discussion/quadramet-epar-scientific-discussion_en.pdf
EU-1-97-055,https://www.ema.europa.eu/documents/scientific-discussion/viramune-epar-scientific-discussion_en.pdf
EU-1-98-058,https://www.ema.europa.eu/documents/scientific-discussion/combivir-epar-scientific-discussion_en.pdf
EU-1-98-064,https://www.ema.europa.eu/documents/scientific-discussion/pylobactell-epar-scientific-discussion_en.pdf
EU-1-98-063,https://www.ema.europa.eu/documents/scientific-discussion/rebif-epar-scientific-discussion_en.pdf
EU-1-98-067,https://www.ema.europa.eu/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf
EU-1-98-065,https://www.ema.europa.eu/documents/procedural-steps/optison-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-98-066,https://www.ema.europa.eu/documents/scientific-discussion/exelon-epar-scientific-discussion_en.pdf
EU-1-98-069,https://www.ema.europa.eu/documents/scientific-discussion/plavix-epar-scientific-discussion_en.pdf
EU-1-98-070,https://www.ema.europa.eu/documents/scientific-discussion/iscover-epar-scientific-discussion_en.pdf
EU-1-98-071,https://www.ema.europa.eu/documents/scientific-discussion/xenical-epar-scientific-discussion_en.pdf
EU-1-98-076,https://www.ema.europa.eu/documents/scientific-discussion/novonorm-epar-scientific-discussion_en.pdf
EU-1-98-073,https://www.ema.europa.eu/documents/scientific-discussion/evista-epar-scientific-discussion_en.pdf
EU-1-98-074,https://www.ema.europa.eu/documents/scientific-discussion/optruma-epar-scientific-discussion_en.pdf
EU-1-98-077,https://www.ema.europa.eu/documents/scientific-discussion/viagra-epar-scientific-discussion_en.pdf
EU-1-98-080,https://www.ema.europa.eu/documents/scientific-discussion/aldara-epar-scientific-discussion_en.pdf
EU-1-98-081,https://www.ema.europa.eu/documents/scientific-discussion/comtan-epar-scientific-discussion_en.pdf
EU-1-98-082,https://www.ema.europa.eu/documents/scientific-discussion/comtess-epar-scientific-discussion_en.pdf
EU-1-98-084,https://www.ema.europa.eu/documents/scientific-discussion/simulect-epar-scientific-discussion_en.pdf
EU-1-98-086,https://www.ema.europa.eu/documents/scientific-discussion/coaprovel-epar-scientific-discussion_en.pdf
EU-1-98-085,https://www.ema.europa.eu/documents/scientific-discussion/karvezide-epar-scientific-discussion_en.pdf
EU-1-97-030,https://www.ema.europa.eu/documents/scientific-discussion/insuman-epar-scientific-discussion_en.pdf
EU-1-98-092,https://www.ema.europa.eu/documents/scientific-discussion/prometax-epar-scientific-discussion_en.pdf
EU-1-98-089,https://www.ema.europa.eu/documents/scientific-discussion/pritor-epar-scientific-discussion_en.pdf
EU-1-98-090,https://www.ema.europa.eu/documents/scientific-discussion/micardis-epar-scientific-discussion_en.pdf
EU-1-98-096,https://www.ema.europa.eu/documents/scientific-discussion/temodal-epar-scientific-discussion_en.pdf
EU-1-98-095,https://www.ema.europa.eu/documents/scientific-discussion/emadine-epar-scientific-discussion_en.pdf
EU-1-99-097,https://www.ema.europa.eu/documents/scientific-discussion/beromun-epar-scientific-discussion_en-0.pdf
EU-1-99-100,https://www.ema.europa.eu/documents/scientific-discussion/cetrotide-epar-scientific-discussion_en.pdf
EU-1-99-103,https://www.ema.europa.eu/documents/scientific-discussion/refacto-af-epar-scientific-discussion_en.pdf
EU-1-99-107,https://www.ema.europa.eu/documents/scientific-discussion/rebetol-epar-scientific-discussion_en.pdf
EU-1-99-108,https://www.ema.europa.eu/documents/scientific-discussion/ferriprox-epar-scientific-discussion_en.pdf
EU-1-96-026,https://www.ema.europa.eu/documents/scientific-discussion/invirase-epar-scientific-discussion_en.pdf
EU-1-99-110,https://www.ema.europa.eu/documents/scientific-discussion/sustiva-epar-scientific-discussion_en.pdf
EU-1-99-111,https://www.ema.europa.eu/documents/scientific-discussion/stocrin-epar-scientific-discussion_en.pdf
EU-1-99-109,https://www.ema.europa.eu/documents/scientific-discussion/integrilin-epar-scientific-discussion_en.pdf
EU-1-99-112,https://www.ema.europa.eu/documents/scientific-discussion/ziagen-epar-scientific-discussion_en.pdf
EU-1-99-114,https://www.ema.europa.eu/documents/scientific-discussion/zeffix-epar-scientific-discussion_en.pdf
EU-1-99-116,https://www.ema.europa.eu/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf
EU-1-99-119,https://www.ema.europa.eu/documents/scientific-discussion/novorapid-epar-scientific-discussion_en.pdf
EU-1-99-117,https://www.ema.europa.eu/documents/scientific-discussion/synagis-epar-scientific-discussion_en.pdf
EU-1-99-118,https://www.ema.europa.eu/documents/scientific-discussion/arava-epar-scientific-discussion_en.pdf
EU-1-99-120,https://www.ema.europa.eu/documents/scientific-discussion/ammonaps-epar-scientific-discussion_en.pdf
EU-1-99-122,https://www.ema.europa.eu/documents/scientific-discussion/thyrogen-epar-scientific-discussion_en.pdf
EU-1-99-123,https://www.ema.europa.eu/documents/scientific-discussion/renagel-epar-scientific-discussion_en.pdf
EU-1-99-124,https://www.ema.europa.eu/documents/scientific-discussion/tractocile-epar-scientific-discussion_en.pdf
EU-1-99-125,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-velotab-epar-scientific-discussion_en.pdf
EU-1-99-126,https://www.ema.europa.eu/documents/scientific-discussion/enbrel-epar-scientific-discussion_en.pdf
EU-1-00-129,https://www.ema.europa.eu/documents/scientific-discussion/azopt-epar-scientific-discussion_en.pdf
EU-1-00-130,https://www.ema.europa.eu/documents/scientific-discussion/orgalutran-epar-scientific-discussion_en.pdf
EU-1-00-134,https://www.ema.europa.eu/documents/scientific-discussion/lantus-epar-scientific-discussion_en.pdf
EU-1-00-135,https://www.ema.europa.eu/documents/scientific-discussion/datscan-epar-scientific-discussion_en.pdf
EU-1-00-140,https://www.ema.europa.eu/documents/scientific-discussion/visudyne-epar-scientific-discussion_en.pdf
EU-1-00-142,https://www.ema.europa.eu/documents/scientific-discussion/novomix-epar-scientific-discussion_en.pdf
EU-1-00-143,https://www.ema.europa.eu/documents/scientific-discussion/kogenate-bayer-epar-scientific-discussion_en.pdf
EU-1-00-145,https://www.ema.europa.eu/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf
EU-1-00-146,https://www.ema.europa.eu/documents/scientific-discussion/keppra-epar-scientific-discussion_en.pdf
EU-1-00-149,https://www.ema.europa.eu/documents/scientific-discussion/panretin-epar-scientific-discussion_en.pdf
EU-1-00-152,https://www.ema.europa.eu/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf
EU-1-00-150,https://www.ema.europa.eu/documents/scientific-discussion/actos-epar-scientific-discussion_en.pdf
EU-1-00-155,https://www.ema.europa.eu/documents/assessment-report/luveris-epar-public-assessment-report_en.pdf
EU-1-00-156,https://www.ema.europa.eu/documents/scientific-discussion/trizivir-epar-scientific-discussion_en.pdf
EU-1-00-157,https://www.ema.europa.eu/documents/scientific-discussion/azomyr-epar-scientific-discussion_en.pdf
EU-1-00-160,https://www.ema.europa.eu/documents/scientific-discussion/aerius-epar-scientific-discussion_en.pdf
EU-1-00-161,https://www.ema.europa.eu/documents/scientific-discussion/neoclarityn-epar-scientific-discussion_en.pdf
EU-1-00-162,https://www.ema.europa.eu/documents/scientific-discussion/prandin-epar-scientific-discussion_en.pdf
EU-1-00-163,https://www.ema.europa.eu/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf
EU-1-00-166,https://www.ema.europa.eu/documents/scientific-discussion/neurobloc-epar-scientific-discussion_en.pdf
EU-1-00-165,https://www.ema.europa.eu/documents/scientific-discussion/ovitrelle-epar-scientific-discussion_en.pdf
EU-1-00-164,https://www.ema.europa.eu/documents/scientific-discussion/nutropinaq-epar-scientific-discussion_en.pdf
